title: Molecularly targeted therapies for nonmelanoma skin cancers.
abstract: Over the past two decades, advances in the fields of cancer genetics and molecular biology have elucidated molecular pathways that cause numerous cutaneous malignancies. This in turn has spurred the rational design of molecularly targeted therapies. In this review, we discuss the molecular pathways critical to the development of nonmelanoma skin cancers and the novel pharmacologic agents that target them. Included is a review of vismodegib for basal cell carcinoma, cetuximab for squamous cell carcinomas, imatinib for dermatofibrosarcoma protuberans, and sirolimus for Kaposi's sarcoma.
authors.affiliation: Department of Dermatology, Yale School of Medicine, New Haven, CT 06520-8059, USA.
authors.forename: Lucinda S
authors.initials: LS
authors.lastname: Liu
authors.forename: Oscar R
authors.initials: OR
authors.lastname: Colegio
mesh_terms: D000813:Anilides / Q000627:therapeutic use*; D000903:Antibiotics, Antineoplastic / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001549:Benzamides / Q000627:therapeutic use; D002280:Basal Cell Carcinoma / Q000188:drug therapy*; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy*; D000068818:Cetuximab; D018223:Dermatofibrosarcoma / Q000188:drug therapy; D006801:Humans; D000068877:Imatinib Mesylate; D010879:Piperazines / Q000627:therapeutic use; D011725:Pyridines / Q000627:therapeutic use*; D011743:Pyrimidines / Q000627:therapeutic use; D012514:Sarcoma, Kaposi / Q000188:drug therapy; D020123:Sirolimus / Q000627:therapeutic use; D012878:Skin Neoplasms / Q000188:drug therapy*
chemical_list: D000813:Anilides; D000903:Antibiotics, Antineoplastic; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D001549:Benzamides; C538724:HhAntag691; D010879:Piperazines; D011725:Pyridines; D011743:Pyrimidines; D000068877:Imatinib Mesylate; D000068818:Cetuximab; D020123:Sirolimus